Results: 10
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
- Published in:
- BioDrugs, 2023, v. 37, n. 6, p. 855, doi. 10.1007/s40259-023-00631-4
- By:
- Publication type:
- Article
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer.
- Published in:
- BioDrugs, 2023, v. 37, n. 6, p. 891, doi. 10.1007/s40259-023-00624-3
- By:
- Publication type:
- Article
Malaria Vaccines: Progress to Date.
- Published in:
- BioDrugs, 2023, v. 37, n. 6, p. 737, doi. 10.1007/s40259-023-00623-4
- By:
- Publication type:
- Article
Enzyme Engineering Strategies for the Bioenhancement of l-Asparaginase Used as a Biopharmaceutical.
- Published in:
- BioDrugs, 2023, v. 37, n. 6, p. 793, doi. 10.1007/s40259-023-00622-5
- By:
- Publication type:
- Article
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
- Published in:
- BioDrugs, 2023, v. 37, n. 6, p. 843, doi. 10.1007/s40259-023-00621-6
- By:
- Publication type:
- Article
Patients' Perceptions of Biosimilars: A Systematic Review.
- Published in:
- BioDrugs, 2023, v. 37, n. 6, p. 829, doi. 10.1007/s40259-023-00620-7
- By:
- Publication type:
- Article
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
- Published in:
- BioDrugs, 2023, v. 37, n. 6, p. 757, doi. 10.1007/s40259-023-00617-2
- By:
- Publication type:
- Article
Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
- Published in:
- BioDrugs, 2023, v. 37, n. 6, p. 775, doi. 10.1007/s40259-023-00614-5
- By:
- Publication type:
- Article
Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.
- Published in:
- BioDrugs, 2023, v. 37, n. 6, p. 813, doi. 10.1007/s40259-023-00613-6
- By:
- Publication type:
- Article
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease.
- Published in:
- BioDrugs, 2023, v. 37, n. 6, p. 873, doi. 10.1007/s40259-023-00616-3
- By:
- Publication type:
- Article